Entering text into the input field will update the search result below

Alnylam Pharmaceuticals (ALNY) Q1 2018 Results - Earnings Call Transcript

May 04, 2018 12:55 AM ETAlnylam Pharmaceuticals, Inc. (ALNY)1 Comment
SA Transcripts profile picture
SA Transcripts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2018 Earnings Call May 3, 2018 4:30 PM ET


Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc.

John M. Maraganore - Alnylam Pharmaceuticals, Inc.

Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc.

Manmeet Singh Soni - Alnylam Pharmaceuticals, Inc.

Barry E. Greene - Alnylam Pharmaceuticals, Inc.

Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc.


Terence Flynn - Goldman Sachs & Co. LLC

Ted A. Tenthoff - Piper Jaffray & Co.

Gena Wang - Barclays Capital, Inc.

Madhu Kumar - B. Riley FBR, Inc.

Vincent Chen - Sanford C. Bernstein & Co. LLC

Maury Raycroft - Jefferies LLC

Alan Carr - Needham & Co. LLC

Irina Margine - Cowen and Company

David N. Lebowitz - Morgan Stanley & Co. LLC


Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals Conference Call to discuss First Quarter 2018 Financial Results. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the Company's request. I would now like turn the call over to the Company.

Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc.

Good afternoon. I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maraganore, Chief Executive Officer; Barry Greene, President; Akshay Vaishnaw, President of R&D; Manmeet Soni, Chief Financial Officer; and Yvonne Greenstreet, Executive Vice President and Chief Operating Officer.

For those of you joining via conference call, the slides we have made available via webcast can also be accessed by going to the Investor page of our website, www.alnylam.com.

During today's call, as outlined in slide 2, John will provide some introductory remarks and provide some general context; Akshay will review our R&D progress; Manmeet will review our financials; Barry will provide an update of our commercial readiness

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.